Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias
-
Published:2024-06
Issue:
Volume:192
Page:107790
-
ISSN:0169-5002
-
Container-title:Lung Cancer
-
language:en
-
Short-container-title:Lung Cancer
Author:
Ishidoya Mina,
Makiguchi TomonoriORCID,
Tanaka HisashiORCID,
Miura Toko,
Nunomura Yasuhito,
Miura Dai,
Morimoto Takeshi,
Hasegawa Yukihiro,
Taima KageakiORCID,
Tasaka Sadatomo
Reference30 articles.
1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer;Borghaei;N. Engl. J. Med.,2015
2. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer;Reck;N. Engl. J. Med.,2016
3. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;The Lancet,2019
4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;The Lancet,2016
5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;The Lancet,2017